Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07562087 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
A Phase 2 study, sponsored by Tarsus Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 722
- Enrollment target
NCT07562087 is a Phase 2 study that is active but no longer recruiting, run by Tarsus Pharmaceuticals. The registered enrollment target is 722 participants.
The verdict
NCT07562087, a Phase 2 study, is active but no longer recruiting, sponsored by Tarsus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 722 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Interventions
- DRUG Placebo
- DRUG TP-05 (lotilaner) Low Dose
- DRUG TP-05 (lotilaner) High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07562087
The ClinicalTrials.gov registry entry for NCT07562087 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 722 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tarsus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07562087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07562087 about?
NCT07562087 is a clinical study titled "A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure". This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
What is the current status of trial NCT07562087?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 722 participants. The study started on 2026-03-09. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07562087?
The interventions under investigation include: Placebo (DRUG), TP-05 (lotilaner) Low Dose (DRUG), TP-05 (lotilaner) High Dose (DRUG).
Who is sponsoring clinical trial NCT07562087?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.